Eli Lilly (NYSE:LLY) inks a non-exclusive agreement with DexCom (NASDAQ:DXCM) for the integration of the latter’s continuous glucose monitoring (CGM) devices in both pen- and pump-based platforms in its personalized diabetes management system.
Lilly is designing its system to integrate personalized CGM data with data from glucose-sensing technologies into a compatible software application, called a hybrid-closed loop system, aimed at automating insulin dosing.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.